Brokerages Set Integra LifeSciences Holdings Co. (NASDAQ:IART) Target Price at $23.00

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been given an average rating of “Reduce” by the nine analysts that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $23.00.

Separately, Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday.

Integra LifeSciences Price Performance

IART stock opened at $21.78 on Monday. The business has a 50 day simple moving average of $23.61 and a 200-day simple moving average of $22.27. The company has a market capitalization of $1.68 billion, a P/E ratio of -241.97, a PEG ratio of 0.73 and a beta of 1.23. Integra LifeSciences has a twelve month low of $16.81 and a twelve month high of $34.80. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. During the same period in the previous year, the business posted $0.89 earnings per share. Integra LifeSciences’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Sachem Head Capital Management LP acquired a new position in shares of Integra LifeSciences during the 3rd quarter worth $44,153,000. Soleus Capital Management L.P. purchased a new stake in Integra LifeSciences during the fourth quarter worth about $28,940,000. Paradigm Capital Management Inc. NY grew its position in Integra LifeSciences by 170.3% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after buying an additional 901,600 shares during the period. Lord Abbett & CO. LLC increased its holdings in Integra LifeSciences by 86.8% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after buying an additional 618,773 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Integra LifeSciences during the 4th quarter valued at approximately $8,967,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.